ABBV Price / Book | AbbVie Inc.

AbbVie Inc. Price/Book Ratio

The price-to-book (P/B) ratio compares what the stock market says a company is worth with what the company's own books say it is worth. It is market capitalization divided by shareholder equity, the book value left after subtracting liabilities from assets, and the table shows both amounts. A ratio of 1.0 means market value equals book value; a higher ratio means investors value the company above its net assets, often for brands, software or expected growth the books do not record. A negative ratio means equity is negative. Each point uses the filed share count and the last closing price on or before the equity's reporting date, never today's price.

AbbVie Inc. price/book ratio for the quarter ending 2026-06-30 was -74.82, a change of 1,716.1 year-over-year.
AbbVie Inc. price/book ratio for the quarter ending 2026-03-31 was -57.76, a 122.18% decline year-over-year.
AbbVie Inc. price/book ratio for the quarter ending 2025-12-31 was -123.5, a 230.76% decline year-over-year.
AbbVie Inc. price/book ratio for the quarter ending 2025-09-30 was -154.84, a 367.77% decline year-over-year.
AbbVie Inc. price/book ratio for fiscal 2026 was -74.82.
AbbVie Inc. price/book ratio for fiscal 2025 was -123.5, a 230.76% decline from fiscal 2024.
AbbVie Inc. price/book ratio for fiscal 2024 was 94.44, a 257.60% increase from fiscal 2023.
AbbVie Inc. price/book ratio for fiscal 2023 was 26.41, a 59.44% increase from fiscal 2022.

Available history: 2013-03-31 to 2026-06-30
Data captured: 2026-06-30

Historical Price/Book Ratio

Date	Price/Book Ratio	Market capitalization	Shareholder equity
2026-06-30	-74.82	$444.07B	-$5.94B
2026-03-31	-57.76	$384.47B	-$6.66B
2025-12-31	-123.5	$403.83B	-$3.27B
2025-09-30	-154.84	$409.1B	-$2.64B
2025-06-30	-1,790.92	$327.74B	-$183M
2025-03-31	260.48	$369.88B	$1.42B
2024-12-31	94.44	$314.02B	$3.33B
2024-09-30	57.83	$348.82B	$6.03B
2024-06-30	44.69	$302.88B	$6.78B
2024-03-31	40.17	$321.67B	$8.01B
2023-12-31	26.41	$273.61B	$10.36B
2023-09-30	21.75	$263.1B	$12.09B
2023-06-30	18.48	$237.7B	$12.87B
2023-03-31	21.24	$281.99B	$13.27B
2022-12-31	16.56	$285.8B	$17.25B
2022-09-30	14.84	$237.3B	$15.99B
2022-06-30	18.47	$270.65B	$14.65B
2022-03-31	17.61	$286.73B	$16.28B
2021-12-31	15.54	$239.37B	$15.41B
2021-09-30	14.07	$190.63B	$13.55B
2021-06-30	15.83	$198.95B	$12.57B
2021-03-31	13.94	$191.1B	$13.71B
2020-12-31	14.47	$189.17B	$13.08B
2020-09-30	10.12	$154.58B	$15.27B
2020-06-30	9.86	$144.99B	$14.71B
2020-03-31	-15.2	$112.7B	-$7.42B
2019-12-31	-16.02	$130.93B	-$8.17B
2019-09-30	-13.61	$111.95B	-$8.23B
2019-06-30	-12.55	$107.5B	-$8.57B
2019-03-31	-15.19	$118.88B	-$7.83B
2018-12-31	-16.42	$138.67B	-$8.45B
2018-09-30	-49.03	$143.22B	-$2.92B
2018-06-30	-43.56	$147.02B	-$3.38B
2018-03-31	42.3	$150.3B	$3.55B
2017-12-31	30.29	$154.39B	$5.1B
2017-09-30	21.18	$141.65B	$6.69B
2017-06-30	19.2	$115.4B	$6.01B
2017-03-31	20.78	$103.86B	$5B
2016-12-31	21.95	$101.76B	$4.64B
2016-09-30	15.88	$102.71B	$6.47B
2016-06-30	17.88	$100.82B	$5.64B
2016-03-31	19.9	$92.38B	$4.64B
2015-12-31	24.55	$96.84B	$3.95B
2015-09-30	18.29	$88.95B	$4.86B
2015-06-30	20.21	$111.22B	$5.5B
2015-03-31	67.73	$93.26B	$1.38B
2014-12-31	59.85	$104.26B	$1.74B
2014-09-30	19.81	$92.03B	$4.65B
2014-06-30	17.22	$89.84B	$5.22B
2014-03-31	17.4	$81.73B	$4.7B
2013-12-31	18.7	$84.01B	$4.49B
2013-09-30	19.89	$71.16B	$3.58B
2013-06-30	18.42	$65.54B	$3.56B
2013-03-31	21.84	$64.58B	$2.96B

Annual Price/Book Ratio

Date	Price/Book Ratio	Market capitalization	Shareholder equity
2026-06-30	-74.82	$444.07B	-$5.94B
2025-12-31	-123.5	$403.83B	-$3.27B
2024-12-31	94.44	$314.02B	$3.33B
2023-12-31	26.41	$273.61B	$10.36B
2022-12-31	16.56	$285.8B	$17.25B
2021-12-31	15.54	$239.37B	$15.41B
2020-12-31	14.47	$189.17B	$13.08B
2019-12-31	-16.02	$130.93B	-$8.17B
2018-12-31	-16.42	$138.67B	-$8.45B
2017-12-31	30.29	$154.39B	$5.1B
2016-12-31	21.95	$101.76B	$4.64B
2015-12-31	24.55	$96.84B	$3.95B
2014-12-31	59.85	$104.26B	$1.74B
2013-12-31	18.7	$84.01B	$4.49B

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
Merck & Co., Inc. (MRK)	United States	$365.215B	99.96
JOHNSON & JOHNSON (JNJ)	United States	$652.528B	29.10
ABBOTT LABORATORIES (ABT)	United States	$176.045B	28.47
PFIZER INC (PFE)	United States	$162.042B	31.94
VERTEX PHARMACEUTICALS INC / MA (VRTX)	United States	$132.481B	28.56
BRISTOL MYERS SQUIBB CO (BMY)	United States	$125.637B	12.67
REGENERON PHARMACEUTICALS, INC. (REGN)	United States	$74.751B	21.53
ALNYLAM PHARMACEUTICALS, INC. (ALNY)	United States	$33.420B	54.94
Zoetis Inc. (ZTS)	United States	$29.045B	11.38
INSMED Inc (INSM)	United States	$26.566B	-26.60